Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Ipilimumab + Vopratelimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 16 Immune Checkpoint Inhibitor 95||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), and and in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Vopratelimab||JTX2011|ICOS agonist monoclonal antibody|anti-ICOS|JTX-2011||Vopratelimab (JTX-2011) is a humanized monoclonal antibody against ICOS (inducible co-stimulator molecule) that regulates anti-tumor immune response (Cancer Res 2016;76(14 Suppl):Abstract nr 573).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03989362||Phase II||Ipilimumab + Vopratelimab||Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)||Recruiting|
|NCT04319224||Phase Ib/II||Vopratelimab Nivolumab + Vopratelimab Ipilimumab + Vopratelimab||Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors||Recruiting|